Making A Market In Women’s Health: Endometriosis, Fibroids Emerge As Rx Targets
This article was originally published in Pharmaceutical Approvals Monthly
Candidates like AbbVie’s elagolix and Actavis’ Esmya promise oral therapy without the drawbacks of the artificial menopause induced by available hormone suppression therapy – and may pave the way for newer approaches while expanding the market.
You may also be interested in...
Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.
Before adding Allergan into the mix – and taking on its name – Actavis wants to show investors that it has a solid foundation as a growth pharma with strong brands in GI, CNS and women’s health.
In an interview, Bayer HealthCare’s recently-arrived new chief executive Olivier Brandicourt discusses the five assets that most excite the firm.